Current Evidence of Cannabidiol's Potential as an Anxiolytic Agent

IF 0.2 4区 医学 Q4 PSYCHIATRY
G. Rossi, J. C. A. Reis, J. Hallak, R. G. Santos
{"title":"Current Evidence of Cannabidiol's Potential as an Anxiolytic Agent","authors":"G. Rossi, J. C. A. Reis, J. Hallak, R. G. Santos","doi":"10.3928/00485713-20230515-02","DOIUrl":null,"url":null,"abstract":"\n This article will summarize the current knowledge and scientific evidence regarding cannabidiol as a possible pharmacological tool for anxiety disorders. Although the use of this substance in medical practice is gaining momentum, gaps can still be found in the current knowledge regarding its molecular targets, drug-to-drug interactions, efficacy in different populations, adequate dosage, duration of treatment, and correct formulation. Moreover, current evidence is still preliminary, lacking robust, blinded, and placebo-controlled clinical trials in many areas of investigation. After reading this article, readers should have a thorough understanding of the current scientific evidence regarding the use of CBD as an anxiolytic drug.\n \n [\n Psychiatr Ann\n . 2023;53(6):242–246.]\n \n","PeriodicalId":20917,"journal":{"name":"Psychiatric Annals","volume":" ","pages":""},"PeriodicalIF":0.2000,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Psychiatric Annals","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3928/00485713-20230515-02","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PSYCHIATRY","Score":null,"Total":0}
引用次数: 0

Abstract

This article will summarize the current knowledge and scientific evidence regarding cannabidiol as a possible pharmacological tool for anxiety disorders. Although the use of this substance in medical practice is gaining momentum, gaps can still be found in the current knowledge regarding its molecular targets, drug-to-drug interactions, efficacy in different populations, adequate dosage, duration of treatment, and correct formulation. Moreover, current evidence is still preliminary, lacking robust, blinded, and placebo-controlled clinical trials in many areas of investigation. After reading this article, readers should have a thorough understanding of the current scientific evidence regarding the use of CBD as an anxiolytic drug. [ Psychiatr Ann . 2023;53(6):242–246.]
大麻二酚作为焦虑剂潜力的最新证据
本文将总结目前关于大麻二酚作为治疗焦虑症的可能药物工具的知识和科学证据。尽管这种物质在医疗实践中的使用势头越来越大,但在其分子靶点、药物间相互作用、不同人群的疗效、足够的剂量、治疗持续时间和正确的配方方面,目前的知识仍存在差距。此外,目前的证据仍然是初步的,在许多研究领域缺乏强有力的、盲法和安慰剂对照的临床试验。读完这篇文章后,读者应该彻底了解目前关于CBD作为一种抗焦虑药物的科学证据。[精神病学年鉴,2023;53(6):242–246.]
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Psychiatric Annals
Psychiatric Annals PSYCHIATRY-
CiteScore
0.90
自引率
0.00%
发文量
77
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信